The Lancet. Global health
-
The Lancet. Global health · Apr 2019
Randomized Controlled TrialEffect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial.
Novartis Access is a Novartis programme that offers a portfolio of non-communicable disease medicines at a wholesale price of US$1 per treatment per month in low-income and middle-income countries. We evaluated the effect of Novartis Access in Kenya, the first country to receive the programme. ⋯ Sandoz International (a subsidiary of Novartis International).
-
The Lancet. Global health · Apr 2019
Meta AnalysisSevere mental illness and substance use disorders in prisoners in low-income and middle-income countries: a systematic review and meta-analysis of prevalence studies.
Although more than two thirds of the world's incarcerated individuals are based in low-income and middle-income countries (LMICs), the burden of psychiatric disorders in this population is not known. This review provides estimates for the prevalence of severe mental illness and substance use disorders in incarcerated individuals in LMICs. ⋯ CONICYT of the Chilean government and the Wellcome Trust.